ESR1 and breast cancer: The impact of BAZ1B on ERα activity in hormone-responsive BC cells suggested the hypothesis that this protein could be an exploitable target to disrupt ERα-mediated signaling also in AE-resistant BC models that recapitulate the endocrine therapy-resistant tumor phenotype [55].